https://www.selleckchem.com/products/TGX-221.html
DIM may act as a novel therapeutic to restrain autoimmune inflammation in multiple sclerosis.Omalizumab is an anti-IgE humanized monoclonal antibody approved for the treatment of severe asthma and chronic spontaneous urticaria. Omalizumab binds free serum IgE and antagonizes its interaction with FcεRI, which is considered the main pharmacodynamic mechanism responsible for the clinical response to the treatment. The reduction of IgE serum concentration down-regulates the cellular expression of FcεRI on basophils. However, the biological
Like
Comment
Share
